Decrease of tyrosine hydroxylase-, α-synuclein- and parkin-expressing neurons in the substantia nigra of MPTP-treated C57BL/6N mice

被引:0
作者
Kitamura, Y [1 ]
Sanada, H
Kakimura, J
Ishida, Y
Shimohama, S
Taniguchi, T
机构
[1] Kyoto Pharmaceut Univ, Dept Neurobiol, Kyoto 6078412, Japan
[2] Kyoto Univ, Grad Sch Med, Dept Neurol, Kyoto 6068501, Japan
关键词
MPTP; alpha-synuclein; parkin; tyrosine hydroxylase; substantia nigra; C57BL/6N mouse;
D O I
暂无
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Recently, mutations in the alpha -synuclein (PARK1) and parkin (PARK2) genes have been identified from patients with the familial Parkinson's disease and parkinsonism, respectively. Systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is known to damage the nigrostriatal dopaminergic system in C57BL/6 mice, in this study, we have investigated changes of immunoreactivities for alpha -synuclein, parkin and tyrosine hydroxylase (TH) in MPTP-treated C57BL/6N mouse brains. Immunoreactivities for alpha -synuclein, parkin and TH were differentially distributed in the mouse brain. MPTP treatment caused significant decrease of the number of TH-, alpha -synuclein- and parkin-immunopositive neurons in the substantia nigra, although these immunoreactivities were not markedly changed in the striatum. These results suggest that alpha -synuclein and parkin may participate in MPTP-induced dopaminergic neurodegeneration in the substantia nigra.
引用
收藏
页码:127 / 136
页数:10
相关论文
共 29 条
[1]  
Clayton DF, 1999, J NEUROSCI RES, V58, P120, DOI 10.1002/(SICI)1097-4547(19991001)58:1<120::AID-JNR12>3.0.CO
[2]  
2-E
[3]   CHRONIC PARKINSONISM SECONDARY TO INTRAVENOUS-INJECTION OF MEPERIDINE ANALOGS [J].
DAVIS, GC ;
WILLIAMS, AC ;
MARKEY, SP ;
EBERT, MH ;
CAINE, ED ;
REICHERT, CM ;
KOPIN, IJ .
PSYCHIATRY RESEARCH, 1979, 1 (03) :249-254
[4]   Prospects for new restorative and neuroprotective treatments in Parkinson's disease [J].
Dunnett, SB ;
Björklund, A .
NATURE, 1999, 399 (6738) :A32-A39
[5]   Cloning of rat parkin cDNA and distribution of parkin in rat brain [J].
Gu, WJ ;
Abbas, N ;
Lagunes, MZ ;
Parent, A ;
Pradier, L ;
Bohme, GA ;
Agid, Y ;
Hirsch, EC ;
Raisman-Vozari, R ;
Brice, A .
JOURNAL OF NEUROCHEMISTRY, 2000, 74 (04) :1773-1776
[6]  
Hashimoto M, 1999, BRAIN PATHOL, V9, P707
[7]   The cDNA cloning and ontogeny of mouse α-synuclein [J].
Hong, L ;
Ko, HW ;
Gwag, BJ ;
Joe, E ;
Lee, S ;
Kim, YT ;
Suh, YH .
NEUROREPORT, 1998, 9 (06) :1239-1243
[8]   Nitric oxide synthase and neuronal vulnerability in Parkinson's disease [J].
Hunot, S ;
Boissiere, F ;
Faucheux, B ;
Brugg, B ;
MouattPrigent, A ;
Agid, Y ;
Hirsch, EC .
NEUROSCIENCE, 1996, 72 (02) :355-363
[9]   THE PRECURSOR PROTEIN OF NON-A-BETA COMPONENT OF ALZHEIMERS-DISEASE AMYLOID IS A PRESYNAPTIC PROTEIN OF THE CENTRAL-NERVOUS-SYSTEM [J].
IWAI, A ;
MASLIAH, E ;
YOSHIMOTO, M ;
GE, NF ;
FLANAGAN, L ;
DESILVA, HAR ;
KITTEL, A ;
SAITOH, T .
NEURON, 1995, 14 (02) :467-475
[10]   Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism [J].
Kitada, T ;
Asakawa, S ;
Hattori, N ;
Matsumine, H ;
Yamamura, Y ;
Minoshima, S ;
Yokochi, M ;
Mizuno, Y ;
Shimizu, N .
NATURE, 1998, 392 (6676) :605-608